Development of Human mAbs to Target Cardiomyocytes and Cardiac Fibroblasts

Sponsor: Silver Creek Pharmaceuticals, Inc.

Location(s): United States


Coronary heart disease is the single biggest killer in the United States accounting for 1 in 5 deaths and affecting over a million people each year. Despite advances in medical care, the one year survival rate following a heart attack is only 37% and no current therapy will significantly regenerate the damaged cardiac tissue. One potential therapeutic approach to regenerating cardiac tissue is stem cell therapy. Although this is a very complicated therapeutic approach, this is the focus of significant research and exploratory medicine both academically and commercially. Using principles of engineering and network biology, we are pioneering an entirely new platform of bio-therapeutics (Smart Growth FactorsTM) that can promote resilience and even regeneration of cardiac cells, while minimizing unwanted effects in other tissues. The first of these molecules have been designed to aid the recovery and regeneration of cardiac tissue in patients who have recently suffered a heart attack or who suffer from ischemic heart disease. The molecules are "systems optimized" to increase local growth factor exposure in the diseased tissues while minimizing exposure in other normal tissues.